Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal Study
- Authors
- Chau, Angela; Yeh, Ming-Lun; Tsai, Pei-Chien; Huang, Daniel Q.; Kim, Sung Eun; Trinh, Huy; Yoon, Eileen L.; Oh, Hyunwoo; Jeong, Jae Yoon; Ahn, Sang Bong; An, Jihyun; Tseng, Cheng-Hao; Hsu, Yao-Chun; Jeong, Soung Won; Cho, Yong Kyun; Shim, Jae-Jun; Kim, Hyoung Su; Ito, Takanori; Marciano, Sebastián; Kawashima, Keigo; Suzuki, Takanori; Watanabe, Tsunamasa; Nozaki, Akito; Ishikawa, Toru; Inoue, Kaori; Eguchi, Yuichiro; Uojima, Haruki; Abe, Hiroshi; Takahashi, Hirokazu; Chuma, Makoto; Ishigami, Masatoshi; Hoang, Joseph K.; Maeda, Mayumi; Huang, Chung-Feng; Gadano, Adrian; Dai, Chia-Yen; Huang, Jee-Fu; Tanaka, Yasuhito; Chuang, Wan-Long; Lim, Seng Gee; Cheung, Ramsey; Yu, Ming-Lung; Jun, Dae-Won; Nguyen, Mindie H.
- Issue Date
- Mar-2024
- Publisher
- W. B. Saunders Co., Ltd.
- Keywords
- Antiviral Therapy; Biochemical Response; Complete Response; Virologic Response
- Citation
- Clinical Gastroenterology and Hepatology, v.22, no.3, pp 572 - 580
- Pages
- 9
- Indexed
- SCIE
SCOPUS
- Journal Title
- Clinical Gastroenterology and Hepatology
- Volume
- 22
- Number
- 3
- Start Page
- 572
- End Page
- 580
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/198138
- DOI
- 10.1016/j.cgh.2023.09.002
- ISSN
- 1542-3565
1542-7714
- Abstract
- Background & Aims: It is unclear if there may be sex differences in response to nucleos(t)ide analogs including virologic response (VR), biochemical response (BR), complete response (CR), and hepatocellular carcinoma (HCC) incidence among hepatitis B patients. We compared nucleos(t)ide analog treatment outcomes by sex. Methods: We performed a retrospective cohort study of 3388 treatment-naïve adult hepatitis B patients (1250 female, 2138 male) from the Real-World Evidence from the Global Alliance for the Study of Hepatitis B Virus consortium who initiated therapy with either entecavir or tenofovir from 22 sites (Argentina, Korea, Japan, Taiwan, and the United States). We used propensity-score matching to balance background characteristics of the male and female groups and competing-risks analysis to estimate the incidence and subdistribution hazard ratios (SHRs) of VR, BR, CR, and HCC. Results: Females (vs males) were older (52.0 vs 48.6 y); less likely to be overweight/obese (49.3% vs 65.7%), diabetic (9.9% vs 13.1%), or cirrhotic (27.9% vs 33.0%); and had a lower HBV DNA level (5.9 vs 6.0 log10 IU/mL) and alanine aminotransferase level (91 vs 102 IU/L) (all P <.01). However, after propensity-score matching, relevant background characteristics were balanced between the 2 groups. Females (vs males) had similar 5-year cumulative VR (91.3% vs 90.3%; P =.40) and HCC incidence rates (5.1% vs 4.4%; P =.64), but lower BR (84.0% vs 90.9%; P <.001) and CR (78.8% vs 83.4%; P =.016). Males were more likely to achieve BR (SHR, 1.31; 95% CI, 1.17–1.46; P <.001) and CR (SHR, 1.16; 95% CI, 1.03–1.31; P =.016), but VR and HCC risks were similar. Conclusions: Sex differences exist for treatment outcomes among hepatitis B patients. Male sex was associated with a 16% higher likelihood of clinical remission and a 31% higher likelihood of biochemical response than females, while virologic response and HCC incidence were similar between the 2 groups.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.